The recent legal settlement between Johnson & Johnsonand a number of states over off-label marketing for Risperdal (risperidone) shows a continuing concern among states with the dissemination of article reprints to health care professionals or entities.
The settlement agreement includes of a number of restrictions on reprints, indicating states remain concerned that federal policy...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?